Brazil
  • pt
  • en
    • Search

    GNOM

    Genomics & Biotechnology ETF

    Invest in GNOM

    Reasons to Consider GNOM

    High Growth Potential

    Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1

    Structural Tailwinds

    Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 37% compound annual growth rate from 2024-2030.2

    Targeted Exposure

    GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.

    1International Society for Cell and Gene Therapy, Feb 2019
    2Evaluate Pharma, n.d., Technology Overviews of: Cell Therapy, Gene Therapy, Gene-Modified Cell Therapy, and Genome Editing, all accessed 6 Jun 2025.

    Key Information As of 02/27/26

    Inception Date 04/05/19
    Total Expense Ratio 0.50%
    Net Assets $52.38 million
    NAV $47.85

    ETF Summary

    The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.

    ETF Objective

    The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.

    Trading Details As of 02/27/26

    Ticker GNOM
    B3 Trading Code BGNO39
    Bloomberg Index Ticker SOLGNOM
    CUSIP 37960A214
    ISIN US37960A2143
    Primary Exchange Nasdaq
    Shares Outstanding 1,094,672
    Number of Holdings 49
    30-Day Median Bid-Ask Spread 0.55%

    Distributions As of 02/27/26

    30-Day SEC Yield -0.07%
    Distribution Frequency Semi Annually
     Distribution History

    ETF Prices As of 02/27/26

    NAV $47.85 Daily Change -$0.01 -0.02%
    Market Price $47.67 Daily Change -$0.14 -0.29%

    Performance History

    Premium Discount Chart
    Cumulative Returns (as of 02/27/26)
    		1 Month 6 Months YTD 12 Months 24 Months Since Inception Inception Date
    Return GNOM 4.92% 32.47% 4.92% 19.09% 1.54% -20.60% 04/05/19
    Returns (as of 02/26/26)
    		Return GNOM Return Index
    Since Inception -20.47% -17.69%
    12 Months 51.84% 52.14%
    24 Months 7.35% 8.23%
    Last 60 Trading Days 4.98% 5.00%
    Last 75 Trading Days 12.90% 13.00%
    Monthly Returns (through 02/26/26)
    		Return GNOM Return Index
    Feb 2026 0.18% 0.19%
    Jan 2026 4.93% 4.97%
    Dec 2025 -0.31% -0.33%
    Nov 2025 2.11% 2.16%
    Oct 2025 16.93% 16.97%
    Sep 2025 5.87% 5.98%
    Aug 2025 5.75% 5.77%
    Jul 2025 3.10% 3.11%
    Jun 2025 8.62% 8.68%
    May 2025 -5.25% -5.25%
    Apr 2025 2.14% 2.06%
    Mar 2025 -13.01% -12.97%
    Feb 2025 -9.25% -9.20%
    Jan 2025 4.84% 4.87%
    Dec 2024 -10.43% -10.37%
    Nov 2024 4.53% 4.55%
    Oct 2024 -7.83% -7.80%
    Sep 2024 -1.42% -1.26%
    Aug 2024 -1.88% -1.86%
    Jul 2024 11.10% 11.20%
    Jun 2024 2.86% 2.88%
    May 2024 3.26% 3.28%
    Apr 2024 -13.27% -13.23%
    Mar 2024 -5.41% -5.20%
    Feb 2024 11.62% 11.55%

    Total returns take into account management, administration and fees and other costs automatically deducted from the fund's assets. Before investing, you may read the prospectus in the “FEES AND EXPENSES” section for more details.

    NAV & Index Chart

    Top Holdings As of 02/27/26

    Full Holdings (.csv)
    Net Assets (%) Ticker Name Country SEDOL Market Price ($) Shares Held Market Value ($)
    8.16 MRNA MODERNA INC United States BGSXTS3 53.57 79,794 4,274,564.58
    6.47 PRAX PRAXIS PRECISION MEDICINES I United States BQ721R4 336.75 10,068 3,390,399.00
    5.91 ARWR ARROWHEAD PHARMACEUTICALS IN United States BYQBFJ8 63.27 48,918 3,095,041.86
    5.32 ILMN ILLUMINA INC United States 2613990 134.46 20,740 2,788,700.40
    4.89 GH GUARDANT HEALTH INC United States BFXC911 93.90 27,272 2,560,840.80
    4.48 VRTX VERTEX PHARMACEUTICALS INC United States 2931034 496.83 4,724 2,347,024.92
    4.48 BMRN BIOMARIN PHARMACEUTICAL INC United States 2437071 61.73 38,005 2,346,048.65
    4.06 NTRA NATERA INC United States BYQRG48 208.04 10,222 2,126,584.88
    4.01 BNTX BIONTECH SE-ADR United States BK6H543 110.23 19,070 2,102,086.10
    3.77 QGEN QIAGEN N.V. United States BVPJWL3 49.80 39,677 1,975,914.60
    3.62 CRSP CRISPR THERAPEUTICS AG United States BDHF4K6 60.14 31,504 1,894,650.56
    3.58 TECH BIO-TECHNE CORP United States BSHZ3Q0 59.00 31,779 1,874,961.00
    2.76 BMY BRISTOL-MYERS SQUIBB CO United States 2126335 62.37 23,133 1,442,805.21
    2.60 ALNY ALNYLAM PHARMACEUTICALS INC United States B00FWN1 332.92 4,093 1,362,641.56
    2.48 VCYT VERACYTE INC United States BFTWZY0 36.59 35,527 1,299,932.93
    2.43 LLY ELI LILLY & CO United States 2516152 1,051.99 1,211 1,273,959.89
    2.38 TWST TWIST BIOSCIENCE CORP United States BGKG6G7 46.92 26,623 1,249,151.16
    2.36 GILD GILEAD SCIENCES INC United States 2369174 148.95 8,316 1,238,668.20
    2.36 AZN LN ASTRAZENECA PLC United Kingdom 0989529 208.95 5,925 1,238,052.57
    2.29 BEAM BEAM THERAPEUTICS INC United States BK6L288 28.46 42,186 1,200,613.56
    2.24 TXG 10X GENOMICS INC-CLASS A United States BKS3RS7 23.05 51,011 1,175,803.55
    2.22 LEGN LEGEND BIOTECH CORP-ADR United States BMX9K07 19.00 61,342 1,165,498.00
    1.85 RARE ULTRAGENYX PHARMACEUTICAL IN United States BJ62Z18 23.39 41,412 968,626.68
    1.78 WGS GENEDX HOLDINGS CORP United States BR841G5 79.71 11,704 932,925.84
    1.56 WVE WAVE LIFE SCIENCES LTD United States BYZG9R0 13.93 58,760 818,526.80
    1.51 1548 HK GENSCRIPT BIOTECH CORP Hong Kong BD9Q2J2 1.53 516,918 789,041.49
    1.36 SRPT SAREPTA THERAPEUTICS INC United States B8DPDT7 16.76 42,658 714,948.08
    1.23 NTLA INTELLIA THERAPEUTICS INC United States BYZM6C2 13.78 46,917 646,516.26
    0.83 CDNA CAREDX INC United States BP3YM74 18.76 23,223 435,663.48
    0.75 QURE UNIQURE NV United States BJFSR88 15.63 25,238 394,469.94
    0.72 VIR VIR BIOTECHNOLOGY INC United States BK4PZ38 9.09 41,784 379,816.56
    0.42 PSNL PERSONALIS INC United States BJQ0608 9.06 24,526 222,205.56
    0.40 PACB PACIFIC BIOSCIENCES OF CALIF United States B4N8MH9 1.68 124,395 208,983.60
    0.40 A AGILENT TECHNOLOGIES INC United States 2520153 121.38 1,720 208,773.60
    0.37 RCKT ROCKET PHARMACEUTICALS INC United States BDFKQ07 5.01 39,105 195,916.05
    0.37 PRME PRIME MEDICINE INC United States BPBJFM7 4.62 42,340 195,610.80
    0.37 RGNX REGENXBIO INC United States BZ0G875 9.04 21,322 192,750.88
    0.36 MYGN MYRIAD GENETICS INC United States 2614153 4.61 40,852 188,327.72
    0.36 MLAB MESA LABORATORIES INC United States 2553814 96.57 1,927 186,090.39
    0.33 MRVI MARAVAI LIFESCIENCES HLDGS-A United States BMCWKZ2 3.56 48,589 172,976.84
    0.33 STOK STOKE THERAPEUTICS INC United States BJQ05Z6 36.41 4,706 171,345.46
    0.27 LAB STANDARD BIOTOOLS INC United States B3D32T9 1.13 124,217 140,365.21
    0.27 FLGT FULGENT GENETICS INC United States BYQBFQ5 15.33 9,121 139,824.93
    0.25 ARCT ARCTURUS THERAPEUTICS HOLDIN United States BKC9SX3 8.23 15,659 128,873.57
    0.23 CRBU CARIBOU BIOSCIENCES INC United States BNYJR68 1.90 62,371 118,504.90
    0.22 SANA SANA BIOTECHNOLOGY INC United States BMFJJ97 4.21 27,527 115,888.67
    0.21 SGMO SANGAMO THERAPEUTICS INC United States 2573083 0.43 254,860 110,175.98
    0.20 EDIT EDITAS MEDICINE INC United States BZ8FPH3 2.20 48,625 106,975.00
    0.20 CASH United States 1.00 102,811 102,811.30
    0.08 RNA ATRIUM THERAPEUTICS INC United States BVPN4Z3 14.75 2,725 40,192.28
    -0.15 OTHER PAYABLE & RECEIVABLES United States 1.00 -76,607 -76,606.96
    Holdings are subject to change. "Cash" denotes U.S. dollars.

    Sector Breakdown As of 01/31/26

    Sector Weight (%)
    Health Care 100.0

    Source: AltaVista Research, LLC

    Country Breakdown As of 01/31/26

    Country Weight (%)
    United States 83.1
    Netherlands 5.0
    Germany 4.0
    Switzerland 2.9
    Britain 2.0
    China 1.6
    Singapore 1.4

    Source: AltaVista Research, LLC

    ETF Characteristics As of 02/27/26

    Return on Equity -15.60%
    Weighted Avg. Market Cap 50,953 M
    2025 2026
    Price-to-earnings -24.83 -35.84
    Price-to-book value 5.13 6.13

    Source: AltaVista Research, LLC

    ETF Risk Stats As of 02/28/26

    Versus Beta
    S&P 500 1.06
    MSCI EAFE 1.17
    MSCI Emg. Mkts 0.98
    Standard Deviation 189.30%

    Source: AltaVista Research, LLC

    ETF Documents

    TERMS OF USE

    Global X Brasil Gestora de Investimentos Ltda. (“Global X Brasil”) is an asset manager authorized by the Brazilian Securities and Exchange Commission (“CVM”), constituted in the form of CVM Resolution No. 21/2021. Investing involves risks. The material on this site is for informational purposes only and does not constitute investment advice, recommendation, offer or solicitation to buy or sell any securities, funds, or strategies to any person in any jurisdiction in which an offer, solicitation, purchase, or sale would be illegal under the securities laws of such jurisdiction. Opinions expressed here are subject to change without notice. Reliance upon the information contained in this material is at the sole discretion of the reader. No securities regulator has confirmed the accuracy of any information contained herein. Access to the information on this site or the use of the services or information provided herein is prohibited by any person or entity in any jurisdiction or country where such distribution or use is contrary to local law, rules, or regulation. Investment in index funds (ETFs) involves risks, including detachment from the benchmark index and related to the liquidity of shares in the secondary market. Investment funds managed by Global X Brasil use strategies that can result in significant equity losses for their quota holders. Global X Brasil, its partners and employees are exempt of responsibility for any damages resulting directly or indirectly from the use of the information contained on this website.

    FOR EVALUATION OF THE PERFORMANCE OF AN INVESTMENT FUND, IT IS RECOMMENDED THE ANALYSIS OF AT LEAST 12 (TWELVE) MONTHS. INVESTMENT FUNDS DO NOT HAVE A GUARANTEE FROM THE ADMINISTRATOR, THE MANAGER, ANY INSURANCE MECHANISM OR CREDIT GUARANTEE FUND – FGC. INVESTMENTS IN FINANCIAL AND CAPITAL MARKETS ARE SUBJECT TO RISKS OF LOSS GREATER THAN THE TOTAL VALUE OF INVESTED CAPITAL. PAST PROFITABILITY DOES NOT REPRESENT A GUARANTEE OF FUTURE PROFITABILITY THE PROFITABILITY DISCLOSED IS NOT NET OF TAXES. READ THE PROSPECTUS, THE FORM OF COMPLEMENTARY INFORMATION, SHEET OF ESSENTIAL INFORMATION AND THE REGULATION BEFORE INVESTING. DESCRIPTION OF THE ANBIMA TYPE AVAILABLE IN THE FORM OF COMPLEMENTARY INFORMATION.

    Back to Top